To verify the performance of DyRAMO, we conducted molecular design in the context of drug design. As a drug target, EGFR, which is targeted in the development of anticancer drugs , was selected. Drug design requires the optimization of pharmacokinetic properties in addition to activity against drug targets, as these properties are essential for drug efficacy and safety . Here, we considered two pharmacokinetic properties and addressed three: inhibitory activity against EGFR, metabolic stability, and membrane permeability. In adjusting the reliability levels, each property can be weighted in the DSS score. The reliability level of each property was standardized by Scaler in the calculation of the DSS score. The Scaler has an adjustable parameter σ (Fig. ), which is used to weight each property in adjusting reliability levels. Reducing the σ makes the Scaler stricter and more sensitive to fluctuations in reliability levels.